G20 Project: Promoting the Leap-forward Development of Beijing Biomedicine

Under the background of the continuous deepening of the impact of the international financial crisis and the slowing down of domestic economic growth, such growth is impressive: the sales revenue of Beijing biomedical industry increased from 39.4 billion yuan at the end of 2009 to 102.3 billion yuan in 2012 The "driving force" of leapfrog development is the leapfrog development project of Beijing Biomedical Industry launched and implemented by Beijing on April 23, 2010 The project is called G20 project for short G is the initial of great in English, which means the key enterprises with large scale and great contribution; 20 means the most important 20% of the "28" principle, which means that 80% of the resources support 20% of the key enterprises "In order to implement the action plan of science and Technology Beijing and the important measures of building Zhongguancun National Independent Innovation Demonstration Zone, the G20 project, under the leadership of the municipal leaders, is an important action for Beijing to adjust its industrial structure in depth and accelerate the transformation of economic growth mode." Yan Aoshuang, director of Beijing Municipal Science and Technology Commission, told reporters, "in the development of biomedical industry, Beijing has unique talent, resources and market advantages The G20 project initiated and implemented by Beijing Municipal Party committee and Beijing municipal government is to follow the principle of innovating working mechanism, strengthening top-level design, focusing on supporting objects and increasing contribution scale, and promote the transformation of biomedical industry from small scattered weak to high concentrated strong, so as to make it become a new pillar industry with strategic significance in the capital " It is particularly important to innovate the working mechanism, strengthen overall coordination, build a long-term mechanism for collaborative promotion, and implement the G20 project well At the beginning of the project, Beijing has established G20 working group to jointly study and solve the major mechanism problems of the development of biomedical industry The G20 working group also set up a Beijing Biomedical Industry Advisory meeting composed of well-known experts at home and abroad, which was held regularly to put forward constructive opinions and suggestions to provide a scientific basis for the government's decision-making How to concentrate the superior forces and build the innovation engine of biomedicine? The G20 project focuses on large and small projects Through project guidance, enterprises are encouraged to rely on the implementation of "large variety strategy", give full play to the guiding role of government funds, and encourage and support enterprises to increase R & D investment and strengthen scientific and technological innovation as the endogenous power to achieve sustainable development Beijing Municipal Science and Technology Commission, in conjunction with relevant departments, organized and implemented "planned, systematic and step-by-step" six kinds of projects, including major national special projects, municipal overall planning, pilot project of Zhongguancun modern service industry, strategic emerging industry, cutting-edge technology, and ministerial and municipal consultation In terms of the organization mode of science and technology plan, they adopt various ways such as open bidding, bidding invitation, excellent selection, entrustment and stable support; the funding arrangement adopts various ways such as free funding, loan discount, government capital equity investment, etc., to mobilize the superior resources of the whole society to promote the development of biomedical industry At the same time of emphasizing the guidance of the government, organize and carry out activities such as technology research, technology integration, achievement transformation, platform building and standard creation On the basis of respecting the market choice, the working group formulated the selection criteria for three types of enterprises, namely, scale enterprises, potential enterprises and introduced enterprises, and jointly screened and identified 50 G20 enterprises With the support of "one enterprise, one policy", "multiple enterprises, one policy" and "one enterprise, multiple policies", Beijing Municipal Commission of science and technology has established more than 100 biomedical enterprise archives and enterprise service specialist systems with G20 enterprises as the main body, so as to timely understand the development of enterprises, In view of the specific problems such as the new GMP, drug bidding, certification of key laboratories of enterprises, etc., a coordination meeting is held regularly, and support measures are formulated to provide enterprises with "close, close and thoughtful" services, so as to make policy resources fall on the demand, in the enterprise and in the industry Yan Aoshuang, director of optimizing the industrial environment and opening up the biomedical industry, believes that basic research and technological research and development are the forerunner of the biomedical industry, but not the whole of the biomedical industry Only by establishing a one-stop innovation chain of research, production and use, and opening up the key links involving basic research, technological development, new drug development, clinical trials, production approval, bidding and procurement, and inclusion in medical insurance, can the biomedical industry grow smoothly and rapidly To this end, Beijing Science and Technology Commission coordinated the joint operations of relevant departments of the city, made efforts to optimize the industrial environment, made articles - issued the key policies of biomedical in bidding procurement, medical insurance catalog and other aspects, increased the support for innovative pharmaceutical varieties; built the platform of biomedical field in the capital, gathered scientific and technological innovation resources, and realized open sharing; In view of the key technical links of the industrial chain, a number of international CMO (biopharmaceutical contract production) / CrO (biomedical R & D outsourcing) public service platforms will be built to provide services for innovative varieties; medical interaction will be strengthened, and 17 top three hospitals will be organized to form a "clinical cro alliance" to increase the support for clinical trials and research of drugs of G20 enterprises; Launch the construction of biomedical achievements post (achievements transformation and undertaking platform in biomedical field), and actively promote the implementation and transformation of scientific and technological achievements in accordance with the principle of "international leading projects, self screening projects and enterprise based projects"; The "Beijing Biomedical Innovation promotion platform" was established jointly with the SFDA and other departments to set up green channels for new drug research, achievement transformation, large-scale production of products, clinical application, etc It's no wonder that a G20 enterprise leader laments that the G20 project is worthy of the "first try" initiative of China's strategic emerging industries It has built a platform for close dialogue among the government, enterprises and market, opened up the two supervision channels for the development of biomedical industry, and created a rare and good environment for enterprise innovation To establish a talent system of "breeding union" to provide intellectual support for biomedical innovation if innovation is the life of biomedical, then talent is the lifeblood of biomedical Without high-end innovative talents, biomedicine is impossible In promoting the G20 project, Beijing Municipal Commission of science and technology takes talent gathering as the top priority, with the core of "attracting overseas leading talents", "linking up" local high-end talents and "cultivating" application talents, and strives to establish the talent system of "selection Association" of G20 project, comprehensively carry out "G20 talent action", and provide strong intellectual support for the leapfrog development of biomedical industry Up to now, G20 project has attracted 25 overseas high-end talent teams and 96 leading soldiers represented by Dr Wang Xiaodong, academician of American Academy of Sciences, tumor R & D and innovation team to Beijing for innovation and entrepreneurship In the "thousand talents plan" implemented by the Central Organization Department, 62 scientists in Beijing's biomedical field were selected, ranking first among all kinds of imported talents At the same time, Beijing Science and Technology Commission attaches great importance to the cultivation of local talents In July 2011, they launched the G20 project application-oriented personnel training plan, and promoted 12 biomedical enterprises, including minhai biology, to work together with Beijing City University and Beijing Electronic Technology Vocational College to build two training bases; jointly held "G20 project advanced seminar" with competent departments, and sang Guowei, vice chairman of the standing Committee of the National People's Congress and chief engineer of national major new drug creation project The first lesson was taught by academicians, and entrepreneurs benefited a lot Talents gather and industries flourish The new drug "Kaishi" developed by Liu Hongxing's team has become the first one billion yuan local breed in Beijing; 12 talent teams, including Lou Bailiang, chairman of KANGLONG Huacheng, have undertaken 8 public service platforms for G20 projects, including "public service platform for chemical synthesis and screening", "public service platform for medical testing" In 2011, the revenue reached 700 million yuan, accounting for 50% of the total revenue of the ABO alliance 。 Driven by innovation, Beijing's biomedical industry is growing rapidly The river is as green as blue in spring With the strong support of the G20 project, Beijing's biomedical industry is in full swing and has delivered a beautiful answer sheet The industrial scale has grown by leaps and bounds, and G20 enterprises have become the leading force Statistics show that in the three years since the implementation of the project, the industrial sales revenue has increased from 39.4 billion yuan at the end of 2009 to 102.3 billion yuan in 2012, with a compound annual growth rate of 37% 50 G20 enterprises have become the leading force in the leapfrog development of Beijing's biomedical industry, with sales revenue growing from 24.3 billion yuan in 2009 to 45.39 billion yuan in 2012; their contribution to the pharmaceutical manufacturing industry has remained above 50% for three consecutive years The innovation driven effect is prominent, and "heavy variety" supports the industrial development From 2010 to 2012, Beijing obtained 295 clinical approval documents for new drugs, ranking first in China; 25 new drug certificates were approved, and the first batch of internationally competitive heavy-duty products, such as long-acting human insulin analogues "insulin glargine" and "alo" (atorvastatin calcium), were cultivated; the first 2 billion yuan variety "betaine apple" and the first locally cultivated 1 in Beijing were cultivated One billion yuan variety "Kaishi", the first domestic medical device variety "intravascular drug (rapamycin) eluting stent delivery system" in Beijing The total number of products above 500 million yuan reached 19, including 6 large varieties of products above 1 billion yuan In addition, the effect of resource investment is significant, and multinational pharmaceutical enterprises are gathering By the end of 2012, the G20 project had 46 investment projects, including 11 major projects with a total investment of 23.17 billion yuan At present, 24 multinational pharmaceutical enterprises, such as Pfizer, Ge, Bayer, Sanofi and Novartis, have established their headquarters, R & D centers or production bases in Beijing Among them, Bayer pharmaceutical moved the global management team of general medicine to Beijing, the global headquarters of general X-ray products business to Beijing, and Novo Nordisk Denmark expanded its global R & D center in Beijing As a typical case of science and technology department leading the development of industry, G20 project has been highly valued and fully recognized by Beijing Municipal Party committee and government, and the second phase plan was launched at the beginning of this year The second phase of the project will be implemented in December 2015 The overall goal is: by the end of the 12th Five Year Plan, the sales revenue of biomedical industry will reach about 180 billion yuan, becoming a pillar industry in Beijing "We will strengthen innovation driven, promote market driven, highlight talent driven and promote internationalization, strive to make biomedical industry a pillar industry of the capital as soon as possible, and make new and greater contributions to the construction of Beijing as a global innovation center!" When it comes to the future of the G20 project, Yan Aoshuang, director of the Beijing Municipal Science and Technology Commission, is full of confidence.